tiprankstipranks
Trending News
More News >
Veracyte (VCYT)
NASDAQ:VCYT
US Market

Veracyte (VCYT) Stock Forecast & Price Target

Compare
489 Followers
See the Price Targets and Ratings of:

VCYT Analyst Ratings

Strong Buy
8Ratings
Strong Buy
7 Buy
0 Hold
1 Sell
Based on 8 analysts giving stock ratings to
Veracyte
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

VCYT Stock 12 Month Forecast

Average Price Target

$39.67
▲(42.03%Upside)
Based on 8 Wall Street analysts offering 12 month price targets for Veracyte in the last 3 months. The average price target is $39.67 with a high forecast of $45.00 and a low forecast of $29.00. The average price target represents a 42.03% change from the last price of $27.93.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"19":"$19","46":"$46","25.75":"$25.8","32.5":"$32.5","39.25":"$39.3"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":45,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$45.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":39.67,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$39.67</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":29,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$29.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[19,25.75,32.5,39.25,46],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Aug<br/>2024","6":"Nov<br/>2024","9":"Feb<br/>2025","12":"May<br/>2025","25":"May<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,29.71,30.886153846153846,32.06230769230769,33.238461538461536,34.41461538461539,35.59076923076923,36.76692307692308,37.94307692307692,39.11923076923077,40.29538461538462,41.47153846153846,42.64769230769231,43.823846153846155,{"y":45,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,29.71,30.476153846153846,31.242307692307694,32.00846153846154,32.77461538461539,33.54076923076923,34.30692307692308,35.073076923076925,35.83923076923077,36.605384615384615,37.371538461538464,38.137692307692305,38.90384615384615,{"y":39.67,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,29.71,29.655384615384616,29.60076923076923,29.546153846153846,29.49153846153846,29.436923076923076,29.38230769230769,29.32769230769231,29.273076923076925,29.21846153846154,29.163846153846155,29.10923076923077,29.054615384615385,{"y":29,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":25.36,"date":1706745600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":21.64,"date":1711929600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":20.13,"date":1714521600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":22.95,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":31.55,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":33.13,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":34.31,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":44.12,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":39.6,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":45.48,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":34.76,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":29.56,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":29.71,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target$45.00Average Price Target$39.67Lowest Price Target$29.00
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
TipRanks Analyst forecast on VCYT
TipRanks AITipRanks
Not Ranked
TipRanks
$32
Buy
14.57%
Upside
Reiterated
05/17/25
Veracyte's overall stock score reflects strong financial performance and positive earnings call sentiment, suggesting potential growth. However, technical indicators reveal bearish momentum, and high valuation levels pose a risk. Despite these challenges, Veracyte's strategic initiatives and robust financials position it well for future opportunities.
Scotiabank Analyst forecast on VCYT
Sung Ji NamScotiabank
Scotiabank
$44
Buy
57.54%
Upside
Reiterated
05/21/25
Scotiabank Reaffirms Their Buy Rating on Veracyte (VCYT)
Morgan Stanley Analyst forecast on VCYT
Tejas SavantMorgan Stanley
Morgan Stanley
$29
Sell
3.83%
Upside
Reiterated
05/20/25
Cautious Outlook on Veracyte: Sell Rating Amid Market Pressures and Execution Risks
Craig-Hallum Analyst forecast on VCYT
William BonelloCraig-Hallum
Craig-Hallum
Buy
Reiterated
05/08/25
Analysts Offer Insights on Healthcare Companies: Delcath Systems (NASDAQ: DCTH), Veracyte (NASDAQ: VCYT) and Inotiv (NASDAQ: NOTV)
William Blair Analyst forecast on VCYT
Andrew BrackmannWilliam Blair
William Blair
Buy
Reiterated
05/08/25
Veracyte's Strong Performance and Promising Growth Opportunities Justify Buy Rating
UBS
$49$42
Buy
50.38%
Upside
Reiterated
05/08/25
Veracyte price target lowered to $42 from $49 at UBSVeracyte price target lowered to $42 from $49 at UBS
Needham
$51$41
Buy
46.80%
Upside
Reiterated
05/08/25
Analysts' Opinions Are Mixed on These Healthcare Stocks: Veracyte (NASDAQ: VCYT), Schrodinger (NASDAQ: SDGR) and Korro Bio (NASDAQ: KRRO)
Leerink Partners Analyst forecast on VCYT
Puneet SoudaLeerink Partners
Leerink Partners
$50$45
Buy
61.12%
Upside
Reiterated
05/08/25
Analysts Offer Insights on Healthcare Companies: Merus (NASDAQ: MRUS), Veracyte (NASDAQ: VCYT) and Crinetics Pharmaceuticals (NASDAQ: CRNX)
Guggenheim Analyst forecast on VCYT
Subbu NambiGuggenheim
Guggenheim
$45$37
Buy
32.47%
Upside
Reiterated
04/09/25
Veracyte price target lowered to $37 from $45 at GuggenheimVeracyte price target lowered to $37 from $45 at Guggenheim
Goldman Sachs Analyst forecast on VCYT
Matthew SykesGoldman Sachs
Goldman Sachs
Hold
Downgraded
12/05/24
Veracyte (VCYT) was downgraded to a Hold Rating at Goldman Sachs
Wolfe Research Analyst forecast on VCYT
Doug SchenkelWolfe Research
Wolfe Research
$50
Buy
79.02%
Upside
Initiated
11/15/24
Veracyte initiated with an Outperform at Wolfe ResearchVeracyte initiated with an Outperform at Wolfe Research
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
TipRanks Analyst forecast on VCYT
TipRanks AITipRanks
Not Ranked
TipRanks
$32
Buy
14.57%
Upside
Reiterated
05/17/25
Veracyte's overall stock score reflects strong financial performance and positive earnings call sentiment, suggesting potential growth. However, technical indicators reveal bearish momentum, and high valuation levels pose a risk. Despite these challenges, Veracyte's strategic initiatives and robust financials position it well for future opportunities.
Scotiabank Analyst forecast on VCYT
Sung Ji NamScotiabank
Scotiabank
$44
Buy
57.54%
Upside
Reiterated
05/21/25
Scotiabank Reaffirms Their Buy Rating on Veracyte (VCYT)
Morgan Stanley Analyst forecast on VCYT
Tejas SavantMorgan Stanley
Morgan Stanley
$29
Sell
3.83%
Upside
Reiterated
05/20/25
Cautious Outlook on Veracyte: Sell Rating Amid Market Pressures and Execution Risks
Craig-Hallum Analyst forecast on VCYT
William BonelloCraig-Hallum
Craig-Hallum
Buy
Reiterated
05/08/25
Analysts Offer Insights on Healthcare Companies: Delcath Systems (NASDAQ: DCTH), Veracyte (NASDAQ: VCYT) and Inotiv (NASDAQ: NOTV)
William Blair Analyst forecast on VCYT
Andrew BrackmannWilliam Blair
William Blair
Buy
Reiterated
05/08/25
Veracyte's Strong Performance and Promising Growth Opportunities Justify Buy Rating
UBS
$49$42
Buy
50.38%
Upside
Reiterated
05/08/25
Veracyte price target lowered to $42 from $49 at UBSVeracyte price target lowered to $42 from $49 at UBS
Needham
$51$41
Buy
46.80%
Upside
Reiterated
05/08/25
Analysts' Opinions Are Mixed on These Healthcare Stocks: Veracyte (NASDAQ: VCYT), Schrodinger (NASDAQ: SDGR) and Korro Bio (NASDAQ: KRRO)
Leerink Partners Analyst forecast on VCYT
Puneet SoudaLeerink Partners
Leerink Partners
$50$45
Buy
61.12%
Upside
Reiterated
05/08/25
Analysts Offer Insights on Healthcare Companies: Merus (NASDAQ: MRUS), Veracyte (NASDAQ: VCYT) and Crinetics Pharmaceuticals (NASDAQ: CRNX)
Guggenheim Analyst forecast on VCYT
Subbu NambiGuggenheim
Guggenheim
$45$37
Buy
32.47%
Upside
Reiterated
04/09/25
Veracyte price target lowered to $37 from $45 at GuggenheimVeracyte price target lowered to $37 from $45 at Guggenheim
Goldman Sachs Analyst forecast on VCYT
Matthew SykesGoldman Sachs
Goldman Sachs
Hold
Downgraded
12/05/24
Veracyte (VCYT) was downgraded to a Hold Rating at Goldman Sachs
Wolfe Research Analyst forecast on VCYT
Doug SchenkelWolfe Research
Wolfe Research
$50
Buy
79.02%
Upside
Initiated
11/15/24
Veracyte initiated with an Outperform at Wolfe ResearchVeracyte initiated with an Outperform at Wolfe Research
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Veracyte

1 Month
xxx
Success Rate
15/23 ratings generated profit
65%
Average Return
+5.63%
reiterated a xxx
rating 23 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 1 Month would result in 65.22% of your transactions generating a profit, with an average return of +5.63% per trade.
3 Months
xxx
Success Rate
16/23 ratings generated profit
70%
Average Return
+17.06%
reiterated a xxx
rating 23 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 69.57% of your transactions generating a profit, with an average return of +17.06% per trade.
1 Year
Tejas SavantMorgan Stanley
Success Rate
10/15 ratings generated profit
67%
Average Return
+4.89%
reiterated a sell rating 24 days ago
Copying Tejas Savant's trades and holding each position for 1 Year would result in 66.67% of your transactions generating a profit, with an average return of +4.89% per trade.
2 Years
xxx
Success Rate
10/15 ratings generated profit
67%
Average Return
+8.57%
reiterated a xxx
rating 24 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 66.67% of your transactions generating a profit, with an average return of +8.57% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

VCYT Analyst Recommendation Trends

Rating
Jan 25
Feb 25
Mar 25
Apr 25
May 25
Strong Buy
0
1
1
1
1
Buy
8
5
7
8
10
Hold
1
1
0
0
0
Sell
1
0
1
1
2
Strong Sell
0
0
0
0
0
total
10
7
9
10
13
In the current month, VCYT has received 11 Buy Ratings, 0 Hold Ratings, and 2 Sell Ratings. VCYT average Analyst price target in the past 3 months is 39.67.
Each month's total comprises the sum of three months' worth of ratings.

VCYT Financial Forecast

VCYT Earnings Forecast

Next quarter’s earnings estimate for VCYT is $0.11 with a range of $0.05 to $0.16. The previous quarter’s EPS was $0.09. VCYT beat its EPS estimate 75.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 58.03% of the time in the same period. In the last calendar year VCYT has Outperformed its overall industry.
Next quarter’s earnings estimate for VCYT is $0.11 with a range of $0.05 to $0.16. The previous quarter’s EPS was $0.09. VCYT beat its EPS estimate 75.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 58.03% of the time in the same period. In the last calendar year VCYT has Outperformed its overall industry.

VCYT Sales Forecast

Next quarter’s sales forecast for VCYT is $121.05M with a range of $117.00M to $123.40M. The previous quarter’s sales results were $114.47M. VCYT beat its sales estimates 100.00% of the time in past 12 months, while its overall industry beat sales estimates 47.51% of the time in the same period. In the last calendar year VCYT has Outperformed its overall industry.
Next quarter’s sales forecast for VCYT is $121.05M with a range of $117.00M to $123.40M. The previous quarter’s sales results were $114.47M. VCYT beat its sales estimates 100.00% of the time in past 12 months, while its overall industry beat sales estimates 47.51% of the time in the same period. In the last calendar year VCYT has Outperformed its overall industry.

VCYT Stock Forecast FAQ

What is VCYT’s average 12-month price target, according to analysts?
Based on analyst ratings, Veracyte’s 12-month average price target is 39.67.
    What is VCYT’s upside potential, based on the analysts’ average price target?
    Veracyte has 42.03% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is VCYT a Buy, Sell or Hold?
          Veracyte has a consensus rating of Strong Buy which is based on 7 buy ratings, 0 hold ratings and 1 sell ratings.
            What is Veracyte’s price target?
            The average price target for Veracyte is 39.67. This is based on 8 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst price target is $45.00 ,the lowest forecast is $29.00. The average price target represents 42.03% Increase from the current price of $27.93.
              What do analysts say about Veracyte?
              Veracyte’s analyst rating consensus is a Strong Buy. This is based on the ratings of 8 Wall Streets Analysts.
                How can I buy shares of VCYT?
                Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.
                  What am I Missing?
                  Make informed decisions based on Top Analysts' activity
                  Know what industry insiders are buying
                  Get actionable alerts from top Wall Street Analysts
                  Find out before anyone else which stock is going to shoot up
                  Get powerful stock screeners & detailed portfolio analysis